|Videos|August 4, 2021
Integrated Early Phase to Commercial Drug Substance to Drug Product
Author(s)Lonza
In this 15-minute talk, David K. Lyon, PhD, Senior Fellow of Research, Lonza, discusses a flexible, integrated model supporting over 600 small molecule therapies.
Related Content
Trending on Pharmaceutical Technology
1
What the OSTP’s New Policy Blueprint Means for Pharma Manufacturing and Development
2
H1 2026 in Review: AI Adoption, Onshoring, and Data Gaps
3
Is Organizational Readiness Pharma's Real AI Barrier in 2026?
4
Regulatory Roundup—July 2026
5